RSPO2 and intestinal neoplasm: Additionally, WNT974 treatment regressed murine intestinal tumours harbouring either Rspo2 or Rspo3 fusion mutations [52], whilst another PORCNi suppressed the growth of RSPO3-mutant patient-derived colon cancer organoids in a xenograft model [61].